Rakuten Medical Announces Trial in Progress Poster Presentation at ASCO 2025 and Enrollment Expansion to Taiwan for Global Phase 3 ASP-1929-381
SAN DIEGO, May 22, 2025 /PRNewswire/ -- Rakuten Medical, Inc., a global biotechnology company developing and commercializing Alluminox™ platform-based photoimmunotherapy, today announced that it will present a Trial in Progress poster at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, which will take place May 30 – June 3, 2025, in Chicago, Illinois.
The poster will feature Rakuten Medical's ongoing global Phase 3 clinical trial evaluating ASP-1929 photoimmunotherapy in combination with pembrolizumab (anti-PD-1) as a first-line therapy for patients with recurrent head and neck squamous cell carcinoma (HNSCC) (Protocol number: ASP-1929-381 / Acronym: ECLIPSE / ClinicalTrials.gov Identifier: NCT06699212 ). The poster will also highlight interim findings from the completed Phase 1b/2 study (ASP-1929-181 / ClinicalTrials.gov Identifier: NCT04305795 ) which evaluated ASP-1929 photoimmunotherapy in combination with anti-PD-1 in recurrent or metastatic HNSCC.
'We are honored that our Trial in Progress poster has been accepted for presentation at ASCO 2025,' said Anastasios Maniakas, MD, PhD, Assistant Professor in the Department of Head and Neck Surgery and an investigator of the ASP-1929-381 study at The University of Texas MD Anderson Cancer Center. 'This Phase 3 study represents a significant step forward in evaluating the potential synergistic efficacy of ASP-1929 photoimmunotherapy and pembrolizumab as a first-line treatment for patients with recurrent HNSCC. We look forward to sharing our progress with the global oncology community and advancing innovative approaches for the treatment of patients facing this challenging disease.'
Rakuten Medical is also pleased to announce that it has recently initiated patient enrollment in Taiwan as part of its global expansion of the Phase 3 ASP-1929-381 study. Currently, over 10 clinical sites across the United States and Taiwan are actively enrolling patients. Additional sites are expected to be activated in both regions, with patient enrollment in Japan anticipated to begin shortly.
'We are pleased to be part of this global Phase 3 study and to contribute to the development of an innovative treatment approach like photoimmunotherapy,' said Kai-Ping Chang, MD, PhD, Professor of the Department of Otolaryngology - Head & Neck Surgery and Principal Investigator of the ASP-1929-381 study at Chang Gung Memorial Hospital in Taiwan. 'Head and neck cancer ranks third in male cancer incidence and fourth in male cancer mortality in Taiwan1. Local recurrence or metastasis is one of the leading causes of death in these patients2, and nearly half of those with recurrent or metastatic disease survive for less than one year3. By participating in this trial, we hope to help advance new therapeutic options that may prolong overall survival of patients with recurrent HNSCC, both in Taiwan and around the world.'
ASCO attendees are invited to visit Rakuten Medical at booth #33110 to learn more about the ASP-1929-381 study and the company's broader Alluminox™ platform.
Rakuten Medical's Trial in Progress Poster Overview
Rakuten Medical Exhibit Booth
About ASP-1929-381 Study
The ASP-1929-381 study is a multi-regional multi-center, randomized, open-label Phase 3 trial, designed to assess the efficacy and safety of ASP-1929 photoimmunotherapy in combination with pembrolizumab as a first-line treatment for locoregional recurrent HNSCC without distant metastases. 412 patients globally will be randomized to either an experimental arm receiving ASP-1929 photoimmunotherapy in combination with pembrolizumab, or a control arm receiving the current pembrolizumab-based standard of care (SOC), where patients may receive pembrolizumab alone or in combination with chemotherapy according to the physician's choice.
The primary endpoint is Overall Survival (OS), with key secondary endpoints including Complete Response Rate (CRR) and Overall Response Rate (ORR).
Disclaimer: Rakuten Medical's Alluminox™ platform-based photoimmunotherapy is investigational outside Japan.
About Rakuten Medical, Inc.
Rakuten Medical, Inc. is a global biotechnology company developing and commercializing Alluminox™ platform-based photoimmunotherapy, which, in pre-clinical studies, has been shown to induce rapid and selective cell killing. Rakuten Medical's photoimmunotherapy is currently investigational outside Japan. Rakuten Medical is committed to its mission to conquer cancer by developing its pioneering treatments as quickly as possible to as many patients as possible all over the world. The company has offices in 5 countries/regions, including the United States, where it is headquartered, Japan, Taiwan, Switzerland and India. For more information, visit www.rakuten-med.com.
About Alluminox™ platform
The Alluminox™ platform is Rakuten Medical's investigational technology platform that combines pharmaceuticals, medical devices, medical technology, and other peripheral technologies. Rakuten Medical is developing Alluminox platform-based photoimmunotherapy, which involves two key steps: 1) drug administration and 2) targeted illumination using medical devices. The drug component consists of a cell-targeting moiety conjugated to a light-activatable dye, such as IRDye® 700DX (IR700), that selectively binds to the surface of targeted cells, such as tumor cells. The device component consists of a light source that locally illuminates the targeted cells with red light (690nm) to transiently activate the drug. Rakuten Medical's pre-clinical data have shown that this activation elicits rapid and selective necrosis of targeted cells through a biophysical process that compromises the membrane integrity of the targeted cells. Therapies developed on the Alluminox platform may also result in local and systemic innate and adaptive immune activation due to immunogenic cell death of the targeted tumor cells and/or the removal of targeted immunosuppressive cells within the tumor microenvironment. Photoimmunotherapy was originally developed by Dr. Hisataka Kobayashi and his team at the National Cancer Institute in the United States. Outside Japan, Rakuten Medical's Alluminox platform-based photoimmunotherapy is investigational.
About ASP-1929
Rakuten Medical's first pipeline drug developed on its Alluminox™ platform is ASP-1929, an antibody-dye conjugate comprised of the anti-EGFR antibody cetuximab and IRDye® 700DX, a light activatable dye. ASP-1929 binds to epidermal growth factor receptor (EGFR), a cancer antigen expressed in multiple types of solid tumors, including head and neck, breast, lung, colorectal, prostate and pancreatic cancers. After binding to cancer cells, ASP-1929 is locally activated by illumination with red light (690 nm), emitted by a laser device system to produce a photochemical reaction. This reaction is believed to cause damage to the membrane of cancer cells, leading to selective necrosis of cancer cells. In Japan, ASP-1929 received marketing approval from the Japanese Ministry of Health, Labor, and Welfare for unresectable locally advanced or recurrent head and neck cancer in September 2020, under the Sakigake Designation System and the Conditional Early Approval System. ASP-1929 photoimmunotherapy in combination with pembrolizumab is currently under investigation in a global Phase 3 clinical trial as a first-line therapy for recurrent head and neck cancer. Outside Japan, ASP-1929 has not yet been approved for commercial use by any regulatory authority.
Contact Us
View original content to download multimedia: https://www.prnewswire.com/news-releases/rakuten-medical-announces-trial-in-progress-poster-presentation-at-asco-2025-and-enrollment-expansion-to-taiwan-for-global-phase-3-asp-1929-381-302463811.html
SOURCE Rakuten Medical, Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 minutes ago
- Yahoo
RetinaClear Vision Formula Gains Attention as Non-Prescription Eye Support Option in 2025
Non-Prescription Vision Supplement RetinaClear Gains Momentum as Consumers Seek Natural Eye Support in 2025 Chicago, June 07, 2025 (GLOBE NEWSWIRE) -- As public interest in alternative vision health options grows, a non-prescription supplement called RetinaClear has entered the spotlight. Designed for adults seeking daily eye support, RetinaClear is marketed as a vision health solution that may help support macular function, retinal response, and overall ocular performance with consistent use. Available exclusively online, RetinaClear is being promoted via its official website, where eligible customers can access various purchasing options and informational videos. The formulation is presented as a natural approach to eye wellness, with the brand suggesting it may assist users looking to protect vision clarity as they age. Although RetinaClear is not a medication and is not intended to diagnose, treat, cure, or prevent any disease, its creators emphasize the importance of taking proactive steps for ocular health. The website explains how poor circulation, oxidative stress, and lifestyle choices can contribute to age-related vision concerns—factors the supplement aims to address through consistent daily use. Consumer interest in vision support supplements has grown significantly in 2025, driven by increasing screen exposure and a desire for proactive wellness strategies. RetinaClear joins a crowded yet competitive marketplace of non-prescription products targeting eye health support. Those interested in learning more or securing a supply of RetinaClear can visit the product's official website: Promotional offers and multi-bottle bundles may be available for first-time buyers. About RetinaClear RetinaClear is a dietary supplement marketed as a natural vision support formula. It is not a prescription drug and should not be used as a substitute for medical advice, diagnosis, or treatment. Individuals are encouraged to consult their healthcare provider before beginning any new supplement regimen. Media Contactsupport@ E 35th Dr #100Aurora, CO 80011 USA(US) 1-302-496-4906(INT) +44-7727-682993 DISCLAIMER: The statements made herein have not been evaluated by the Food and Drug Administration. Products mentioned are not intended to diagnose, treat, cure, or prevent any disease. This release contains affiliate links. As an independent publication, we may receive a commission from qualifying purchases made through the links provided. CONTACT: support@ 19655 E 35th Dr #100 Aurora, CO 80011 USA (US) 1-302-496-4906 (INT) +44-7727-682993
Yahoo
19 minutes ago
- Yahoo
What I'm hearing about NCAA revenue sharing: $40M football rosters, unintended consequences
The House v. NCAA settlement, granted final approval Friday, has been touted as a means of restoring order to this Big Money Era of college sports. Starting this summer, Power 4 and other Division I schools can begin directly paying their athletes via an annual revenue sharing pool capped at roughly $20.5 million per school in year one. But because schools have been preparing to navigate this new world order — and how to gain a competitive edge under it — many in the industry expect the budding NIL arms race to continue at the top of the sport, and at a price point much higher than the cap. Advertisement 'The top (football) teams are going to cost $40-50 million a year,' said one power conference personnel director. 'That's where this is going. Anyone who thinks different is nuts.' That projected 'budget' includes additional NIL (name, image and likeness) payments from collectives and outside organizations to athletes on top of the capped revenue sharing from the school. It would be a steep increase from the market-setting $20 million in NIL money Ohio State funded its roster with last season on the way to a national championship. But most significantly, a number of industry sources believe that $40 million-$50 million rate will continue beyond this upcoming season, where a number of top-end rosters have been uniquely built with front-loaded, pre-settlement NIL deals. This cuts directly against the intent of the settlement, which is designed to stamp out the unspoken pay-for-play deals that have hijacked the NIL marketplace and keep ballooning roster budgets in check. 'No chance,' the personnel director said. Advertisement It's one of the many changes, intended and unintended, coming to college sports under the House settlement. Schools opting in have spent the past year bracing for the financial reckoning this settlement will bring, including where the revenue share money will come from and how it will be distributed. College athletics have been trending in this direction, and to the benefit of most athletes, particularly those in revenue sports who will receive a bigger cut of the billions in television, sponsorship and ticket revenues that pour into power conference athletic departments. Many of those same departments, however, are already struggling with the challenges of this transition. 'We're all just trying to figure it out as we go through it,' said one power conference head football coach. 'The whole deal is to make it a level playing field, but I don't think that will ever be realistic.' Advertisement spoke with more than a dozen sources across each of the Power 4 conferences about how they plan to approach this new revenue sharing model and all that will come with it — including in-fighting between coaches at the same school, why 'tanking' could factor into college sports and how programs will continue to bend rules and find competitive advantages in a post-settlement era. The sources include athletic directors and administrators; coaches, general managers and personnel staffers in football and men's basketball; and others involved in NIL and collectives. All were granted anonymity in exchange for their candor. 'F— Deloitte. This is going to get even crazier' The $20.5 million revenue sharing cap goes into effect July 1 and covers every sport under a school's athletic department. The most prominent football programs expect to have about $15 million of that pool at their disposal, with top programs supplementing that budget with third-party, 'over-the-cap' NIL deals. Advertisement But not so fast, my friends. The settlement includes a new oversight and enforcement arm — named the College Sports Commission — that requires outside deals from collectives and other associated companies and organizations to reflect a valid business purpose and fall within an approved range of compensation. The settlement establishes a clearinghouse, dubbed NIL Go and managed by the accounting firm Deloitte, which instructs athletes to self-report any third-party NIL deals worth $600 or more for review. The idea is that any of those deals that fail to meet a valid business purpose and/or fall within an approved range will be flagged, and must be adjusted or taken to arbitration. From the perspective of the NCAA and power conference leadership, this new enforcement is meant to bring competitive balance and transparency to a lawless, untenable NIL marketplace. But among those who have witnessed the NCAA's inability to police that marketplace in the past, there's a lot of skepticism that the settlement will change things. 'It all sounds great in theory, but how will it actually work?' asked one power conference athletic director. Industry sources familiar with the clearinghouse and enforcement plan insist it will have more (and swifter) latitude and punitive power than the NCAA wielded in the NIL era. Until it actually drops that hammer, it's done little to scare off coaches and recruiting staffs with passionate, deep-pocketed donors. Advertisement A number of sources questioned whether athletes will even report their third-party deals, or do so accurately. Others suggested that deals getting challenged by the clearinghouse — or the fact that they have to be disclosed at all — could spark more antitrust legal action from collectives. Other sources were outright dismissive. 'If you tell a booster or business owner they can't give a star player $2 million, there will be lawsuits,' said the personnel director. 'There's no enforcing this. Fair market value? F— Deloitte. This is going to get even crazier.' A legit enforcement arm with some teeth — perhaps in the form of suspensions or ineligibility — might change that sentiment, and multiple athletic directors suggest that if the clearinghouse merely serves as a minor deterrent to egregious pay-for-play payments, it will be better than pre-settlement circumstances. But others think the undertow of NIL and collectives is too strong to turn back now. 'There are a lot of rich people that can't buy a professional sports franchise, but they can give a ton of money to their alma mater,' said a power conference administrator. 'And if you're telling millionaires and billionaires what they can and can't do with their money, you're probably going to lose that battle.' Finding the money The over-the-cap arms race is for high rollers only. It will attract the premier programs that expect to win national championships, but for most schools, even in the power conferences, their focus is on how they will fund a new $20 million budget item. Advertisement Power conference athletic departments operate as self-sustaining organizations with $100 million budgets, where expenses more or less line up with revenues. Operating this way, even as millions upon millions in annual television revenue flowed in, is how the conferences and NCAA became ensnared in so much legal trouble to begin with. Untangling those norms is an admittedly first-class problem, but will require significant budgetary adjustments, including new revenue growth and cost cutting. Most schools are leaning on fundraising and seeking new or increased assistance from campus subsidies or student fees. Virginia Tech, for example, recently announced it will increase student fees and direct a larger portion to athletics to help fund revenue sharing, a path plenty of other schools are considering. Iowa State athletic director Jaime Pollard referenced as much in a recent interview, while noting that Cyclones athletics receive no financial subsidies from the university. 'Iowa State does not have that (additional) $20 million, but if we don't pay it for this coming year, we have big problems, right? So we're going to pay it,' said Pollard. 'Would you pay a bigger fee (as a student) … to go to school here so that a member of our men's basketball team could get paid $1.5 million in addition to their scholarship, their room and board, and all the services they get for being a student on campus? That's the fundamental question we're going to have to ask ourselves. Because if we don't do that, then what we're saying is that we're not going to have the athletics program that we're having.' Even with increased fees and fundraising, there will also be widespread belt-tightening on things like administrative staffing and athlete benefits within athletic departments, such as eliminating Alston payments and reevaluating meal offerings in the facility. Advertisement 'If a player is making $500,000 a year, why am I still paying for three meals a day?' said another power conference administrator. There could be new revenue streams from things like on-field logos or naming rights. Long term, departments might get creative, whether that's an in-stadium restaurant that's open year-round, purchasing its own housing complexes for athletes or inviting private equity. Last December, Oklahoma State coach Mike Gundy and Florida State coach Mike Norvell each restructured lucrative contracts, returning a portion of their salary to the school after disappointing seasons. Kentucky recently announced it is transitioning its athletic department to a nonprofit LLC. Fans will feel it too. Schools such as Tennessee and Arkansas have already increased ticket or concession prices to fund revenue sharing. Some may pass processing fees onto customers, or explore local restaurant and hotel taxes. And the fundraising calls won't stop. Fully eliminating non-revenue varsity sports is another last-resort option for most athletic directors, but it's already begun, at least outside the power conferences. UTEP discontinued women's tennis. Cal Poly did the same with men's and women's swimming and diving. Saint Francis (Pa.) announced plans to reclassify all athletics from Division I to Division III, just one week after its men's basketball team played in the NCAA Tournament. Utah shuttered its women's beach volleyball program, though it did not mention the House settlement and rather cited conference realignment. Advertisement 'I know for a fact schools are definitely talking about it,' said an administrator. By any route, the ability for schools to spend the full amount of that annual revenue sharing cap — which will be essential to staying competitive, particularly at the highest levels — is a significant financial undertaking, and one few athletic departments can cobble together without upending their standard operating procedure. 'Right now it feels like Monopoly. We're planning to spend to the cap, but we have to figure out how we're getting there,' said the power conference athletic director. 'If you cut a million somewhere, sure that helps, but if you cut $5 (million) or $10 million, you're really hurting your department.' Everyone wants their share Generating the money is the first hurdle. Then schools have to decide how to distribute it among their sports. Most FBS athletic departments plan to use the settlement's backpay formula as a blueprint, with roughly 75 percent earmarked to football ($15 million), 15-20 percent to men's basketball, 5-10 percent to women's basketball and whatever is left to the non-revenue sports. Advertisement Certain universities, like Texas Tech, have been transparent with the percentage of funds going to each sport and how those are calculated. But because there are no stipulations for how the pool must be allocated, it will vary between schools. And could create some dicey internal dynamics. 'There is absolutely in-fighting (between coaches),' said an administrator. Head coaches at the same school are essentially vying with one another for a bigger chunk of revenue share. One power conference administrator said their school plans to direct as much as 25 percent to men's basketball, which means less for football. There have also been rumblings about how this could benefit the best-resourced basketball programs in the Big East or WCC that don't have to share with football. 'There are going to be some challenging and difficult conversations,' said another power conference AD. 'Coaches will be paying more attention to the revenue figures of their program than ever before. Everybody wants to make a case why their rev share should increase.' Agreements and innovative approaches Once a school allocates its revenue share dollars, it's up to teams to build out the roster accordingly. 'Rev cap management,' as one AD phrased it. Advertisement Many schools have already signed athletes to preliminary revenue share agreements — whether through collectives or the actual university — specifying that payments will transfer to the athletic department on July 1. In addition to the wave of frontloaded NIL deals in recent months, as collectives emptied the coffers ahead of the settlement, schools are inserting notable caveats into these agreements. Some have buyout clauses, where athletes would have to pay money back to a school if they leave before the end of the agreement, similar to coaching contracts. Some suggest that because compensation is based on NIL, it can be adjusted up or down based on performance and/or playing time. Others have strict injury clauses. 'With some negotiations, we were very direct that if you're not healthy, you're not getting the money,' said another power conference personnel director. Whether any of these stipulations hold up in a legal sense remains to be seen, but it's clear that after years of schools and coaches feeling they were on the short end of the NIL power dynamic, they are attempting to wrest back that control. Still, numerous people consulted for this story said the vast majority of initial revenue share agreements will be for one season until there's clarity on how legally binding these agreements truly are. Repeats of the Nico Iamaleava holdout saga might be less likely for the time being, but there could be standoffs over payment disputes. Unlike in the NFL, where there is a rookie salary scale and fairly transparent free agency, college football teams are still navigating best roster-building practices. How much money do you set aside for high school recruits? For transfers? Which positions do you value most in your particular system? How should you structure a player's payments? This could lead to more GM hires in the mold of Andrew Luck or pro-style executives who have administrative power over head coaches and can maintain philosophies across coaching changes. Advertisement Further complicating matters is the fact that the settlement and revenue share calendars operate on the academic fiscal calendar, which runs July to June. This means each football season is split across two separate rev share budgets. 'If you spend all $15 million on players for the 2025 season, then you aren't going to be able to pay anyone for the 2026 season until July 1, 2026,' explained the personnel director. This will require thoughtful budgeting, and could spark some innovative approaches — some more palatable than others. 'Tanking' has been an issue unique to professional sports, but revenue sharing could usher it into the college ranks. If a team has glaring roster holes at quarterback or other key positions, it could elect to save its revenue share money and go all-in on the transfer portal when the season ends, with a bigger war chest than most of its competitors. 'I do think you will see teams try to manipulate the cap in different ways,' said another power conference personnel director. Ongoing issues From a legal perspective, the lawsuits and court battles won't stop in the wake of the House settlement. A number of states already have NIL laws that contradict the settlement, and the Johnson v. NCAA case regarding athlete employment is still ongoing. Advertisement From a competitive perspective, the dollars going up means the competitive imbalance will too. This isn't a new problem in college sports, but a settlement negotiated with heavy input from the power conferences isn't going to change that, regardless of how well the clearinghouse works. 'It's going to separate, even more, the haves and the have-nots,' said an administrator. Big picture, athletic departments will be forced to adapt, financially and operationally, as college sports lean further away from amateurism and toward a more professional model. 'For the longest time, these athletic departments acted like nonprofits,' said another administrator. 'Now they have to act like businesses.' Advertisement In the meantime, power and non-power programs alike are hoping for some degree of stability in an industry that has had very little in recent years. 'At some point,' said a personnel director, 'maybe we'll get two years in a row where we know what's going on.' This article originally appeared in The Athletic. College Football, Men's College Basketball, Sports Business, Women's College Basketball 2025 The Athletic Media Company
Yahoo
24 minutes ago
- Yahoo
Salmonella outbreak tied to eggs sickens dozens across 7 states
A salmonella outbreak linked to a large egg recall has made dozens of people sick in seven states in the West and Midwest, federal health officials said Saturday. The August Egg Company recalled about 1.7 million brown organic and brown cage-free egg varieties distributed to grocery stores between February and May because of the potential for salmonella, according to a posted announcement Friday on the Food and Drug Administration's website. At least 79 people in seven states have gotten a strain of salmonella that was linked to the eggs, and 21 people have been hospitalized. the U.S. Centers for Disease Control and Prevention said. The recall covers Arizona, California, Illinois, Indiana, Nebraska, New Mexico, Nevada, Washington and Wyoming. A list of brands and plant codes or Julian dates can be found on the FDA and CDC websites. Symptoms of salmonella poisoning include diarrhea, fever, severe vomiting, dehydration and stomach cramps. Most people who get sick recover within a week. Infections can be severe in young children, older adults and people with weakened immune systems, who may require hospitalization. The CDC advises people to throw away recalled eggs or return them to the store where they were purchased. Consumers should also wash and disinfect any surfaces that came in contact with the eggs. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
